Multidrug Resistant Gram-negative Pathogen Infections in High Risk Neonates in the Northeast of Mexico
NCT ID: NCT04812847
Last Updated: 2023-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
597 participants
OBSERVATIONAL
2021-06-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perinatal Transmission of MDR Bacteria
NCT06148480
Dynamic of the Acquisition of Antibiotic Resistance in Integrons in Neonatology Newborns
NCT02434679
Antimicrobial PK in Infants With Suspected or Confirmed Infection
NCT00491426
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
NCT06086626
Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala
NCT05314816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The prospective cohort will allow the estimation of Gram-negative infection burden in the study population, and the characterization of all microorganisms isolates from study subjects at the phenotype and genotype level, specifically in relation to the expression of multi-drug resistance (MDR) associated genes (Molecular characterization of Gram-negative MDR isolates); the cohort will be formed by each neonate, from the admission to special care, the isolation date and then follow-up until the resolution, being it discharge either alive, dead or by transfer to another facility. Risk ratios for each of these outcomes will be calculated.
Cases-controls analysis will allow the research team to identify main risk factors present in those individuals who further had or did not have a gram-negative MDR isolate, by calculation of associated odds ratios for concurrent perinatal factors. Another project goal, to establish correlations and measure risk factors (Odds ratios) between Gram-negative infection with MDR organisms and concurrent illness and treatments offered in the special care nursery (medical \[antibiotics, non-steroid anti-inflammatory drugs, steroids, others\], surgical, and clinical procedures) in neonates under special care, will also be attained through the nested cases and controls study approach.
Finally, a derivative from this project will be the establishment of the North-East Mexico Regional Repository of bacterial isolates in Neonates under special care. At the first stage, this repository will preserve specimens of bacteria, both Gram-negative and Gram-positive, along with a specially developed anonymous database of the individuals hosting those infections. In the near future, the focus of this repository may expand to fungus, parasites and perhaps viral isolates preservation.
The research team has also proposed an exploratory objective, subject to budget availability, and that is the characterization and comparison of the immuno-phenotype of those individuals affected of Gram-negative infection with MDR resistant organisms, those with infection with other organisms and those not affected by infectious complications.
All gram-negative isolates will be probed for the gene expression of 38 selected antibiotic resistance loci, and 96 selected samples will be further studied by next generation sequentiation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gram negative infection, MDR present
Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
Identification of MDR characteristics
Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
Gram negative infection, MDR absent
Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
Identification of MDR characteristics
Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Identification of MDR characteristics
Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Treating physician´s order to draw any biological sample and send it for culture at the hospital´s clinical laboratory.
3. A culture with an isolate of Gram-negative bacteria.
Exclusion Criteria
2. Any culture with Gram-positive bacteria, or fungus growth.
1 Day
180 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Tecnologico y de Estudios Superiores de Monterey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Victor Javier Lara-Diaz, M.D., Ph.D.
Professor-Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victor Javier Lara-Diaz, MD, PhD
Role: STUDY_CHAIR
Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud
Cuauhtémoc Licona-Cassani, PhD
Role: PRINCIPAL_INVESTIGATOR
Tecnológico de Monterrey, Centro de Biotecnología FEMSA
Marion Genevieve Brunck, PhD
Role: PRINCIPAL_INVESTIGATOR
Tecnológico de Monterrey, Escuela de Ingeniería y Ciencias, GIEE on Translational Omics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Regional Materno Infantil de Alta Especialidad, Secretaría de Salud
Guadalupe, Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
InfGNMDR-Neo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.